Clinical trials: Cancer of Nasopharynx
Nasopharyngeal Carcinoma
Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to preliminarily evaluate the efficacy and safety of chemotherapy plus subsequent loco-regional radiotherapy combined with toripalimab for the de novo metastatic nasopharyngeal carcinoma.
- Trial name
- NCT04398056
- Testing
- Chemotherapy plus radiotherapy and Toripalimab
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.
To explore and evaluate the dose-limiting toxicity (DLT) profile of the fixed-dose combination of toripalimab, anlotinib, and chidamide in patients with recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), and to determine…
- Trial name
- NCT07320963
- Testing
- Chidamide, Toripalimab, Anlotinib
- Volunteers
- 52 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Environmental and Genetic Determinants of Nasopharyngeal Carcinoma (NPC)
Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors in southern China and Southeast Asia. While infection with Epstein-Barr Virus (EBV) is believed to be necessary for the development of NPC, non-viral…
- Trial name
- NCT01182909
- Where
- Taiwan
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Far Eastern Memorial Hospital
Nasopharyngeal Cancinoma (NPC)
Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity
This is a an open-label, non-inferiority, multicenter, randomized phase III trial aimed to explore the efficacy and safety of shrinking the anterior border of CTV2 in nasopharyngeal carcinoma patients without tumor invasion into…
- Trial name
- NCT07072000
- Testing
- standard CTV delineation, reduced CTV delineation
- Where
- 5 sites in China
- Volunteers
- 550 people
- Sponsor
- Hai-Qiang Mai,MD,PhD
Nasopharyngeal Carcinoma
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
Hypothesis We hypothesise that intermittent dosing of the anti-angiogenic RTKI sunitinib or bevacizumab prior to systemic cisplatin and gemcitabine chemotherapy to transiently "normalise" tumour vasculature in patients with…
- Trial name
- NCT01309633
- Testing
- 12.5mg sunitinib with Cisplatin and Gemcitabine, 25mg Sunitinib alternating with Cisplatin and Gemcitabine, 7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine
- Where
- Singapore
- Volunteers
- 80 people
- Sponsor
- National University Hospital, Singapore
Nasopharyngeal Carcinoma, Malnutrition
Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC Patients
This is an prospective，open-label, none-interventional, observational， multicenter phase II clinical trial. The purpose of this study is to observe the effect of neoadjuvant chemotherapy followed by concurrent chemoradiation…
- Trial name
- NCT02575547
- Testing
- cisplatin and docetaxel
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Zhao Chong
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
This study plans to enroll patients with histologically or cytologically confirmed locally recurrent nasopharyngeal carcinoma. After signing informed consent, eligible subjects will receive three cycles of standard-dose becotatug…
- Trial name
- NCT07781358
- Testing
- Becotatug Vedotin, PD-1 / PD-L1 monoclonal antibody
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Hongmeng Yu
Nasopharyngeal Carcinoma, Local Recurrence
MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
This study enrolls patients who have experienced local recurrence of nasopharyngeal carcinoma (NPC) with or without regional recurrence.
- Trial name
- NCT07331428
- Testing
- MRG003, Tislelizumab, Capecitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fujian Cancer Hospital
Salivary Gland Cancer, Nasopharyngeal Carcinoma
Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis
Nasopharyngeal carcinoma (NPC) is the tenth leading cancers in Taiwan and investigating its biomarker is important for understanding the mechanism of its pathogenesis.
- Trial name
- NCT02401763
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Nasopharyngeal Carcinoma, Radiation Therapy Complication
Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis
Patients with head and neck cancer who underwent irradiation have a higher risk of developing severe carotid stenosis, and eventually develop to transient ischemic attack or stroke.
- Trial name
- NCT02022293
- Testing
- Atorvastatin
- Where
- 6 sites in China
- Volunteers
- 324 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Nasopharyngeal Carcinoma
To Investigate the Molecular Mechanism of Traditional Chinese Medicine Constitution Using Next-generation Sequencing in Nasopharyngeal Carcinoma
To investigate the molecular mechanism of traditional Chinese medicine constitution, the investigators proposed a randomized, double-blind, placebo-controlled, phase II trial to recruit 120 patients with nasopharyngeal cancer.
- Trial name
- NCT03578575
- Testing
- Danggui Buxue Tang
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- China Medical University Hospital
Cancer of the Pharynx, Cancer of the Larynx
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
The combined use of chemotherapeutic drugs with radiation has proven to be effective in improving overall survival and local control among patients with locally advanced head and neck cancer.
- Conditions
- Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Nasal Cavity, Paranasal Sinus Neoplasms
- Trial name
- DeCIDE (NCT00117572)
- Testing
- docetaxel, cisplatin, hydroxyurea
- Where
- 26 sites in United States, Croatia and 3 more
- Volunteers
- 285 people
- Sponsor
- University of Chicago
Bladder Cancer, Brain and Central Nervous System Tumors
High-dose ICE With Amifostine
The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and…
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor
- Trial name
- NCT00003657
- Testing
- filgrastim, Amifostine, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Nasopharyngeal Carcinoma
Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of sufficient chemoradiotherapy plus oral capecitabine/S-1 for 1 year in the treatment of oligometastatic…
- Trial name
- NCT04319471
- Testing
- Capecitabine/S-1, Chemotherapy, Head and neck radiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma, Radiation Therapy Induced Change
Application of Whole-course Standardized Nutrition Management During Peri-radiotherapy in Patients With Nasopharyngeal Carcinoma After Radiotherapy: a Multicenter Randomized Controlled Clinical Study
This study will present an advanced equipment of tumor nutrition diagnosis and assesment for nasopharyngeal cancer(NPC) radiotherapy patients in nutritional risk screening, evaluation, diagnosis and directing nutritional…
- Conditions
- Nasopharyngeal Carcinoma, Radiation Therapy Induced Change, Nutrition Disorders
- Trial name
- NCT05008471
- Testing
- Formula nutrition
- Where
- China
- Volunteers
- 388 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal and Hypopharyngeal Carcinoma
Expression of Programmed Death Ligand-1 (PD-L1) in Nasopharyngeal and Hyypopharyngeal Carcinoma
Head and neck tumors comprise heterogeneous neoplasms that arise from surface epithelium of different anatomic subsites in head and neck region such as oral cavity, oropharynx, larynx and hypopharynx.
- Trial name
- NCT05595265
- Testing
- immunohistochemical
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Head and Neck Neoplasms
Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma
To assess the efficacy of docetaxel, cisplatin combination in terms of disease free survival. Time to progression of the disease in terms of local and distant failure; assess the survival time, and assess the objective (clinical…
- Trial name
- Tax-Nazo (NCT00772681)
- Testing
- docetaxel and cisplatin
- Where
- Turkey (Türkiye)
- Volunteers
- 57 people
- Sponsor
- Sanofi
HNSCC, Lip SCC
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
This is a prospective, multi-center, open-label, non-randomized, multi-arm phase II trial to evaluate the efficacy of combination therapy with pembrolizumab and cetuximab for patients with recurrent/metastatic HNSCC.
- Conditions
- HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT03082534
- Testing
- Pembrolizumab, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of California, San Diego
Mouth Cancer, Lip Cancer
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients with nasopharyngeal carcinoma (NPC). 2.
- Conditions
- Mouth Cancer, Lip Cancer, Throat Cancer, Lip Neoplasms
- Trial name
- NCT00186433
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.